- Stimulates dopamine receptors in brain, relieving parkinsonian symptoms.
- Paminergic & Dopamine agonist
- Inhibits prolactin, which is responsible for lactation, and lowers elevated blood levels of growth hormone in acromegaly.
- The mechanism in glycemic control is unknown.
- Tablet:1 mg,2.5 mg.
- Capsule: 5 mg ,10 mg .
|Absorption||28% of oral dose absorbed|
|Distribution||90 to 96% bound to serum albumin|
|Metabolism||Primarily metabolized in the GI tract and liver (CYP3A4). Undergoes extensive first-pass metabolism|
|Elimination||Major elimination route is hepatic; 6% is renally eliminated. Terminal half-life of 15 h|
- Treatment of hyperprolactinemia-associated disorders (eg, amenorrhea with or without galactorrhea, infertility, hypogonadism).
- In patients with prolactin-secreting adenomas treatment of acromegaly
- Therapy for Parkinson disease (idiopathic or postencephalitic)
- Therapy for type 2 diabetes
- Hepatic Coma
- Cyclical mastalgia
- Hypersensitivity to bromocriptine, ergot alkaloids or ergot-related drugs, or any component of the product; breast-feeding.
- They should also be avoided in pre-eclampsia
- Uncontrolled hypertension; pregnancy postpartum period in women with a history of coronary artery disease or severe CV conditions
- Postural/orthostatic hypotension , syncope ,cardiac valvulopathy, hypertension, MI, stroke
- Headache, dizziness , fatigue , light-headedness , somnolence ,drowsiness ,confusion, hallucinations, psychomotor agitation, psychotic disorders, seizures
- Rhinitis , sinusitis ,amblyopia dry mouth/nasal stuffiness
- Constrictive pericarditis, pleu
- ral and pericardial effusion, pleural and pulmonary fibrosis, pleural thickening
- Nausea , constipation , diarrhea ,dyspepsia , vomiting anorexia ,abdominal cramps , GI bleeding
- CYP3A4 strong inhibitors (eg, azoleantifungals, protease inhibitors)
- Pharmacologic and toxic effects of bromocriptine may beincreased. Coadminister with caution
- Dopamine antagonists (eg, butyrophenones, metoclopramide, phenothiazine
- Dopamine antagonists may reduce bromocriptine efficacy; bromocriptine may reduce effectiveness of dopamine antagonists. Concurrent use is not recommended
- Coadministration may increase occurrence of ergot-related side effects (eg, fatigue, nausea, vomiting) and may reduce effectiveness of ergot drugs when used to treat migraines.
- Concomitant use is not recommended.
- May increase bromocriptine serum levels
- May potentiate adverse effects of bromocriptine
- Highly protein—bound drugs (eg, chloramphenicol, probenecid, salicylates, sulfonamides)
- Bromocriptine may increase the unbound fraction of other concomitantly used highly protein—bound drugs
- Methyldopa Hypotensive effects may be increased
- Triptans (eg,sumatriptan)
- May have additive vasoconstrictive effects.
- Avoid concomitant use
- Prolactinoma is treated with Alpha-Bromocriptine
- Bromocriptine is paminergic agonists used for parkinsonism which has the potential to cause retroperitoneal fibrosis
- Bromocriptine therapy for mother is Contraindication to breast milk feeding
- To suppress lactation in mother with rheumatic fever, Rx of choice is Bromocriptine
- Bromocriptine is Dopamine agonist that Decreases prolactin release
- Bromocriptine is indicated in Prolactin -secreting adenomas,Amenorrhea - Galactorrhea & Acromegaly
- A young women with secondary amenorrhea and galactorrhea. MRI shows a tumour of < lOmm diameter in the pituitary fossa. Treatment is Bromocriptine
- Bromocriptine is used in Type II DM,Hepatic Coma & Cyclical mastalgia
Don't Forget to Solve all the previous Year Question asked on Bromocriptine